Your browser is no longer supported. Please, upgrade your browser.
Settings
MLNT Melinta Therapeutics, Inc. daily Stock Chart
MLNT [NASD]
Melinta Therapeutics, Inc.
Index- P/E- EPS (ttm)-11.82 Insider Own0.30% Shs Outstand13.57M Perf Week16.49%
Market Cap59.44M Forward P/E- EPS next Y-5.42 Insider Trans- Shs Float12.92M Perf Month35.60%
Income-134.70M PEG- EPS next Q-2.58 Inst Own44.40% Short Float12.59% Perf Quarter13.18%
Sales99.60M P/S0.60 EPS this Y84.30% Inst Trans129.69% Short Ratio3.51 Perf Half Y1.15%
Book/sh12.00 P/B0.37 EPS next Y44.60% ROA-29.40% Target Price12.33 Perf Year-77.31%
Cash/sh6.65 P/C0.66 EPS next 5Y- ROE-72.50% 52W Range1.62 - 20.00 Perf YTD10.51%
Dividend- P/FCF- EPS past 5Y14.80% ROI-51.80% 52W High-78.10% Beta4.47
Dividend %- Quick Ratio0.90 Sales past 5Y65.30% Gross Margin61.50% 52W Low170.37% ATR0.36
Employees290 Current Ratio1.20 Sales Q/Q33.30% Oper. Margin- RSI (14)67.67 Volatility8.49% 10.25%
OptionableYes Debt/Eq0.00 EPS Q/Q55.70% Profit Margin- Rel Volume0.72 Prev Close4.60
ShortableYes LT Debt/Eq1.11 EarningsNov 08 BMO Payout- Avg Volume462.60K Price4.38
Recom2.80 SMA2019.18% SMA5042.68% SMA2003.46% Volume332,672 Change-4.78%
Jun-20-19Reiterated H.C. Wainwright Buy $45 → $13
Jun-20-19Downgrade WBB Securities Speculative Buy → Hold
Jun-14-19Downgrade JP Morgan Neutral → Underweight
May-10-19Downgrade Jefferies Buy → Hold $14 → $5
Dec-20-18Downgrade Gabelli & Co Buy → Hold
Dec-18-18Resumed Ladenburg Thalmann Buy $14
Oct-22-18Upgrade Gabelli & Co Hold → Buy $11.50
Nov-30-17Upgrade Ladenburg Thalmann Neutral → Buy
Nov-30-17Upgrade Gabelli & Co Sell → Hold
Oct-14-19 12:25PM  Who Has Been Selling Melinta Therapeutics, Inc. (NASDAQ:MLNT) Shares? Simply Wall St.
Oct-01-19 10:07AM  Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2019 PR Newswire
Sep-24-19 10:51AM  Implied Volatility Surging for Melinta Therapeutics (MLNT) Stock Options Zacks -7.33%
Sep-04-19 07:08AM  The Daily Biotech Pulse: Puma Leaps, Aerie Borrows, Hepion Back In Nasdaq's Good Books Benzinga
Sep-03-19 04:05PM  Melinta Therapeutics Announces Appointment of Jennifer Sanfilippo to Interim Chief Executive Officer and Director GlobeNewswire
Aug-15-19 12:32PM  What Kind Of Shareholder Appears On The Melinta Therapeutics, Inc.'s (NASDAQ:MLNT) Shareholder Register? Simply Wall St.
Aug-09-19 08:55AM  Melinta Therapeutics, Inc. (MLNT) Reports Q2 Loss, Tops Revenue Estimates Zacks -19.03%
07:31AM  Melinta Therapeutics Names David Gill as Chairman and Announces CEO Succession Plan GlobeNewswire
07:30AM  Melinta Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update GlobeNewswire
Aug-06-19 05:04PM  Melinta Therapeutics Announces Rescheduling of Second Quarter 2019 Financial Results Reporting GlobeNewswire
09:08AM  Cronos (CRON) to Report Q2 Earnings: What's in the Cards? Zacks
Aug-05-19 10:09AM  Is a Beat in Store for Melinta (MLNT) This Earnings Season? Zacks
Jul-31-19 10:36AM  Melinta Therapeutics, Inc. (MLNT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release Zacks
Jul-29-19 05:50PM  Melinta Therapeutics, Inc. (MLNT) Dips More Than Broader Markets: What You Should Know Zacks
Jul-17-19 04:02PM  Melinta (MLNT) Announces Preliminary Product Sales for Q2 Zacks -5.06%
Jul-16-19 07:30AM  Melinta Therapeutics Announces Preliminary Second Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire -5.50%
Jul-05-19 12:50PM  Make Trend Your Friend With This Volume-Focused Trading Tool Benzinga -9.13%
Jul-01-19 09:13AM  X-Biotix Therapeutics Joins Antimicrobials Working Group PR Newswire +6.02%
Jun-20-19 12:35PM  A Look At Benzinga Pro's Most-Searched Tickers For June 20, 2019 Benzinga -17.63%
11:13AM  Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2019 PR Newswire
08:51AM  Options Traders Expect Huge Moves in Melinta Therapeutics (MLNT) Stock Zacks
Jun-19-19 01:25PM  Melinta Therapeutics News: Why MLNT Stock Is Skyrocketing Today InvestorPlace +223.74%
09:25AM  Melinta Therapeutics' stock rockets on heavy volume after FDA accepts sNDA for Baxdela MarketWatch
07:30AM  Melinta Therapeutics Announces U.S. FDA Acceptance of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia GlobeNewswire
Jun-14-19 11:23AM  Those Who Purchased Melinta Therapeutics (NASDAQ:MLNT) Shares A Year Ago Have A 96% Loss To Show For It Simply Wall St. -9.14%
Jun-07-19 09:27AM  Antimicrobials Working Group Commends Senator Isakson and Senator Casey for Introducing Legislation to Improve Access to Innovative Therapies to Fight Drug-Resistant Infections PR Newswire -5.19%
May-09-19 05:15PM  Melinta Therapeutics, Inc. (MLNT) Reports Q1 Loss, Misses Revenue Estimates Zacks
04:55PM  Melinta Therapeutics, Inc.: 1Q Earnings Snapshot Associated Press
04:00PM  Melinta Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
May-07-19 07:30AM  Melinta Therapeutics to Present at Making a Difference in Infectious Diseases (MAD-ID) 2019 Annual Meeting GlobeNewswire -5.66%
May-02-19 04:30PM  Melinta Therapeutics to Report First Quarter 2019 Financial Results on May 9, 2019 GlobeNewswire
Apr-12-19 10:08AM  Antimicrobials Working Group Highlights Member Company Participation at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) PR Newswire
Apr-08-19 07:30AM  Melinta Therapeutics Announces Multiple Presentations at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) GlobeNewswire +15.15%
Mar-14-19 11:48PM  Melinta Therapeutics Inc (MLNT) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com +16.77%
Mar-13-19 05:15PM  Melinta Therapeutics, Inc. (MLNT) Reports Q4 Loss, Tops Revenue Estimates Zacks
04:00PM  Melinta Therapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results GlobeNewswire
Mar-05-19 08:00AM  Melinta Therapeutics to Report Fourth Quarter and Year-End 2018 Financial Results on March 13, 2019 GlobeNewswire
Feb-25-19 09:03AM  TherapeuticsMD (TXMD) Catches Eye: Stock Jumps 6.1% Zacks -9.02%
08:15AM  Melinta Therapeutics Announces Closing of Initial $75 Million Vatera Convertible Loan Funding GlobeNewswire
Feb-21-19 01:30PM  Melinta Therapeutics Announces One-for-Five Reverse Stock Split GlobeNewswire -6.02%
Feb-04-19 08:00AM  Melinta Therapeutics Provides Corporate Updates GlobeNewswire +71.18%
Jan-17-19 10:00AM  Antimicrobials Working Group Announces Updates to Leadership Team PR Newswire
Dec-21-18 08:53AM  Adamis Pharmaceuticals (ADMP) Jumps: Stock Rises 5.3% Zacks -9.78%
Dec-19-18 08:31AM  John H. Johnson Agrees to Become Permanent Chief Executive Officer of Melinta Therapeutics GlobeNewswire -6.09%
08:30AM  Melinta Therapeutics Announces Commitment for New Credit Facility of Up to $135 Million GlobeNewswire
Dec-17-18 07:30AM  Dova Pharmaceuticals Announces Management Changes GlobeNewswire
Dec-11-18 05:44PM  Jazz (JAZZ) Increases Share Buyback Authorization by $400M Zacks -9.68%
Nov-30-18 10:43AM  INVESTIGATION NOTICE:  Kaskela Law LLC Announces Investigation of Melinta Therapeutics, Inc. on Behalf of Stockholders MLNT GlobeNewswire -9.01%
Nov-27-18 08:00AM  Melinta Therapeutics Granted European Commission Marketing Authorization for Vabomere® (meropenem and vaborbactam) GlobeNewswire -6.05%
Nov-26-18 05:57PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by the Board of Directors of Melinta Therapeutics, Inc. GlobeNewswire
Nov-24-18 05:10PM  STOCKHOLDER ALERT: Kaskela Law LLC Announces Investigation of Melinta Therapeutics, Inc. - MLNT ACCESSWIRE
Nov-16-18 07:45AM  New Research: Key Drivers of Growth for Fresh Del Monte Produce, Liquidity Services, B.O.S. Better Online Solutions, ePlus inc, Pluralsight, and Melinta Therapeutics Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire -9.78%
Nov-07-18 04:59PM  Melinta Therapeutics, Inc.: 3Q Earnings Snapshot Associated Press
11:25AM  Melinta Therapeutics, Inc. (MLNT) Reports Q3 Loss, Tops Revenue Estimates Zacks
07:00AM  Melinta Therapeutics Reports Third Quarter 2018 Financial Results GlobeNewswire
Oct-31-18 04:05PM  Melinta Therapeutics Announces Appointment of Bruce L. Downey to Board of Directors GlobeNewswire
Oct-29-18 08:00AM  Melinta Therapeutics Announces Positive Top-Line Results in Phase III Trial of Baxdela® (delafloxacin) for Treatment of CABP GlobeNewswire -15.36%
Oct-26-18 08:00AM  Melinta Therapeutics to Report Third Quarter 2018 Financial Results on November 7, 2018 GlobeNewswire -8.20%
Oct-22-18 08:00AM  Melinta Therapeutics Announces Appointment of John H. Johnson as Interim Chief Executive Officer GlobeNewswire -18.52%
Oct-05-18 08:00AM  Melinta Therapeutics Publishes Findings from Orbactiv® (oritavancin) Real-World Registry Demonstrating Efficacy and Safety Consistent with Phase 3 SOLO Program GlobeNewswire
Oct-02-18 08:00AM  Melinta Therapeutics Publishes Complete Results from Phase III TANGO 2 Study of Vabomere (meropenem and vaborbactam) GlobeNewswire
Oct-01-18 08:15AM  Melinta Therapeutics and Menarini Group Enter Commercial Agreement for Vabomere (meropenem and vaborbactam), Orbactiv® (oritavancin) and Minocin® (minocycline) for Injection in 68 Countries GlobeNewswire +5.82%
Sep-25-18 08:00AM  Melinta Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire -6.74%
Sep-24-18 08:00AM  Melinta Therapeutics to Give New Presentations on Antibiotics Portfolio and Pipeline at IDWeek 2018 GlobeNewswire
Sep-21-18 07:37AM  Melinta Therapeutics Receives Positive CHMP Opinion for Vabomere (meropenem and vaborbactam) GlobeNewswire
Sep-18-18 03:53PM  Are Melinta Therapeutics Incs (NASDAQ:MLNT) Interest Costs Too High? Simply Wall St. +8.54%
08:00AM  Melinta Therapeutics Names Peter Milligan as Chief Financial Officer GlobeNewswire
Sep-06-18 08:00AM  Melinta Therapeutics to Host Meetings at the Morgan Stanley 16th Annual Global Healthcare Conference GlobeNewswire -6.38%
Aug-29-18 08:00AM  Melinta Therapeutics to Present at the Rodman & Renshaw 20th Annual Global Investment Conference GlobeNewswire
Aug-07-18 09:35AM  Melinta Therapeutics, Inc. (MLNT) Reports Q2 Loss, Lags Revenue Estimates Zacks -8.64%
07:00AM  Melinta Therapeutics Reports Second Quarter 2018 Financial Results GlobeNewswire
06:30AM  Melinta Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Aug-03-18 01:31PM  Melinta Therapeutics Announces Vabomere (meropenem and vaborbactam) Granted New Technology Add-On Payment by CMS GlobeNewswire
Jul-11-18 08:00AM  Melinta Therapeutics to Report Second Quarter 2018 Financial Results on August 7, 2018 GlobeNewswire
Jun-13-18 04:05PM  Melinta Therapeutics to Present at the JMP Securities Life Sciences Conference GlobeNewswire
Jun-06-18 10:08AM  Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2018 PR Newswire +9.09%
May-31-18 08:00AM  Melinta Therapeutics Demonstrates Breadth of Commercial and Clinical Programs with 20 Presentations at ASM Microbe 2018 GlobeNewswire
May-29-18 04:05PM  Melinta Therapeutics Announces Closing of Underwritten Public Offering and Exercise in Full of Underwriters Option to Purchase Additional Shares of Common Stock GlobeNewswire
May-24-18 08:00AM  Melinta Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference GlobeNewswire -14.86%
May-23-18 09:07PM  Melinta Therapeutics Announces Pricing of Public Offering of Common Stock GlobeNewswire
May-21-18 04:10PM  Melinta Therapeutics Announces Proposed Offering of Common Stock GlobeNewswire
May-11-18 08:00AM  Melinta Therapeutics Launches New Antibiotic Stewardship Program to Combat Growing Threat of Antimicrobial Resistance GlobeNewswire
May-08-18 04:01PM  Melinta Therapeutics Reports First Quarter 2018 Financial Results GlobeNewswire
08:00AM  Melinta Therapeutics to Highlight Commitment to Antibiotics and Product Portfolio at MAD-ID 2018 Annual Meeting GlobeNewswire
May-07-18 07:00AM  Melinta Therapeutics Receives Up to $6.2 Million from CARB-X to Advance Clinical Development of a Novel Antimicrobial to Combat Antibiotic-Resistant Bacteria GlobeNewswire +5.63%
Apr-27-18 04:15PM  Melinta Therapeutics to Report First Quarter 2018 Financial Results on May 8, 2018 GlobeNewswire
Apr-23-18 08:00AM  Melinta Therapeutics Presents Results from VABOMERE TANGO II Trial at ECCMID 2018, Highlighting Outcomes in Vulnerable Patient Populations GlobeNewswire -6.71%
07:30AM  Melinta Therapeutics Presents Updates on the Pyrrolocytosine Compound RX-P2382 against ESKAPE Pathogens at ECCMID 2018 GlobeNewswire
Apr-20-18 10:17AM  Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) PR Newswire
Apr-16-18 08:00AM  Melinta Therapeutics to Present Detailed Results from Vabomere TANGO II Trial as well as New In Vitro and In Vivo Findings from Baxdela and Pyrrolocytosine Candidate at ECCMID 2018 GlobeNewswire
Mar-14-18 08:00AM  Melinta Therapeutics to Present at Needham & Companys 17th Annual Healthcare Conference GlobeNewswire -6.15%
Mar-13-18 04:35PM  Melinta Therapeutics Cancels Presentation at The Cowen & Company 38th Annual Health Care Conference Due to Inclement Weather GlobeNewswire -9.29%
07:36AM  Cempra reports 4Q loss Associated Press
07:00AM  Melinta Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire
06:45AM  Melinta Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Mar-08-18 07:00AM  Melinta Therapeutics Partner, Menarini Group, Submits Marketing Authorization Application for Delafloxacin in Europe GlobeNewswire
Mar-02-18 07:00AM  Melinta Therapeutics to Present at The Cowen and Company 38th Annual Health Care Conference GlobeNewswire
Feb-28-18 07:00AM  Melinta Therapeutics To Report Fourth Quarter and Full Year 2017 Financial Results on March 13, 2018 GlobeNewswire
Feb-27-18 04:05PM  Melinta Therapeutics Publishes Complete Results from Phase 3 TANGO I Study of VABOMERE (meropenem and vaborbactam) in Patients with cUTI GlobeNewswire
Feb-20-18 07:00AM  Melinta Therapeutics Commercial Partner Eurofarma Laboratórios Submits Marketing Authorization Application for Delafloxacin in Argentina GlobeNewswire
Melinta Therapeutics, Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, a monotherapy treatment of adult patients with acute bacterial skin or skin structure infections (ABSSSIs); Vabomere, an IV antibiotic used in treatment of gram-negative infections; Orbactiv, an IV antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens. The company has license agreements with Yale University, Medical Research Council, Wakunaga Pharmaceutical Co., Ltd., and CyDex Pharmaceuticals, Inc. Melinta Therapeutics, Inc. was founded in 2000 and is based in Morristown, New Jersey.